QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ANGO

QT72AngioDynamics, Inc.
NASDAQ·Healthcare·Medical - Instruments & Supplies·USA
Latest market price
12.15
+0.41+3.49%
OverviewShort InterestFilings
ANGOQT72AngioDynamics, Inc.·NASDAQ
OverviewShort InterestFilings
12.15+3.49%
TA
Loading chart...
Screen all →
BDX+1.67%$143.98ALC+0.84%$64.68MDLN-1.32%$35.94WST+1.35%$327.95COO+1.32%$65.91BAX+2.58%$19.89ATR+0.28%$120.32RGEN-1.15%$132.02
Snapshot
Index-P/E-EPS (ttm)-0.75
Insider Own-
Shs Outstand-
Perf Week0.58%
Market Cap485.08MForward P/E-EPS next Y-0.03Insider Trans-Shs Float-Perf Month6.21%
Enterprise Value447.27MPEG-EPS next Q-Inst Own-Short Float-Perf Quarter14.30%
Income-31190894.00P/S1.55EPS this Y79.12%Inst Trans-Short Ratio-Perf Half Y-9.87%
Sales313.72MP/B2.82EPS next Y80.84%ROA-12.04%Short Interest-Perf YTD-5.37%
Book/sh-P/C109.79EPS next 5Y-ROE-17.65%52W High13.99 -13.15%Perf Year19.59%
Cash/sh-P/FCF322.74EPS past 3/5Y-ROIC-13.03%52W Low8.36 45.33%Perf 3Y-
Dividend Est.-EV/EBITDA-82.17Sales past 3/5Y-2.60% 2.04%Gross Margin53.45%Volatility2.40% 2.54%Perf 5Y-
Dividend TTM-EV/Sales1.43EPS Y/Y TTM-Oper. Margin-8.08%ATR (14)0.41Perf 10Y-
Dividend Ex-Date-Quick Ratio1.47Sales Y/Y TTM2.96%Profit Margin-10.00%RSI (14)57.68Recom2.55
Dividend Gr. 3/5Y-Current Ratio2.35EPS Q/Q-SMA202.70%Beta1.10Target Price16.50
Payout0.00%Debt/Eq0.00Sales Q/Q8.33%SMA507.94%Rel Volume3.45Prev Close11.74
Employees748LT Debt/Eq0.04Earnings-SMA2006.52%Avg Volume346.87KPrice12.15
IPO DateJun 01, 2004Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA6.95Volume1,195,350Change3.49%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-03-25ReiteratedCanaccord GenuityBuy$17 → $18
Jul-16-25ReiteratedCanaccord GenuityBuy$12 → $17
Oct-04-24ReiteratedCanaccord GenuityBuy$12
Sep-20-24ReiteratedH.C. Wainwright$14
Apr-05-24UpgradeOppenheimerPerform → Outperform$12
Apr-17-23DowngradeRaymond JamesStrong Buy → Outperform
Jan-06-23ReiteratedRaymond JamesStrong Buy$27 → $22
Jul-13-22ReiteratedRaymond JamesStrong Buy$27
Oct-15-21UpgradeCanaccord GenuityHold → Buy
Nov-25-20UpgradeRaymond JamesMarket Perform → Strong Buy
Latest News
Jun-17-26
Jun-17-2608:37AM
AngioDynamics Says FDA Approves IDE Application To Initiate RELIEF Study Evaluating NanoKnife IRE Platform As Minimally Invasive Treatment Option For Men With Benign Prostatic HyperplasiaBenzinga
Jun-11-26
Jun-11-2602:31AM
AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - SlideshowSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
5/31/2025
FY 2024
5/31/2024
FY 2023
5/31/2023
FY 2022
5/31/2022
FY 2021
5/31/2021
FY 2020
5/31/2020
FY 2019
5/31/2019
FY 2018
5/31/2018
Total Revenue313292304
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A146135149
Gross Profit167158155
Selling, General and Administrative Excl. Other153145144
Research and Development282632
Other Operating Expense1327171
Operating Income-25-40-192
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)4-16-159
Net Income Before Taxes-31-34-192
Income Taxes00-7
Consolidated Net Income-31-34-184
Net Income From Continuing Operations-31-34-184
Net Income-31-34-184
EPS (Recurring)-0.75-0.83-4.59
EPS (Basic, Before Extraordinaries)-0.75-0.83-4.59
EPS (Diluted)-0.75-0.83-4.59
EBITDA-52-6
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio1.631.43—
Gross Margin53.3554.1150.99
Operating Margin-7.99-13.70-63.16
Net Margin-9.90-11.64-60.53
Shares Outstanding424140
Market Capitalization510418—
Operating Lease Expense
———
Insider Trading Volume
$12.80$11.52$10.23$8.95$7.67● Close Price0.00K59.88K119.77K179.65K239.53KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Weiss Lawrence TSVP, Chief Legal OfficerOct 21 '25Buy11.8110,000118,10093,597Oct 22 12:00 AM
Trowbridge Stephen AEVP and CFOOct 13 '25Buy11.168909,932256,629Oct 14 12:00 AM
Clemmer James CPresident and CEOOct 09 '25Buy11.1510,000111,500882,529Oct 09 12:00 AM
Nighan Warren JRSVP Quality and RegulatoryJan 16 '25Sale12.314,06049,97941,817Jan 17 12:00 AM
Nighan Warren JRSVP Quality and RegulatoryOct 10 '24Buy6.0810060845,877Oct 10 12:00 AM
Nighan Warren JRSVP Quality and RegulatoryOct 07 '24Buy6.097684,67745,777Oct 10 12:00 AM
Trowbridge Stephen AEVP and CFOOct 08 '24Buy5.861,7009,962172,711Oct 08 12:00 AM
Clemmer James CPresident and CEOOct 07 '24Buy6.0320,000120,600681,582Oct 08 12:00 AM
Piccinini LauraSVP InternationalJul 17 '24Option Exercise0.0010,342042,491Aug 02 12:00 AM
Clemmer James CPresident and CEOJul 17 '24Option Exercise0.00108,6570690,312Aug 02 12:00 AM
Nighan Warren JRSVP Quality and RegulatoryJul 17 '24Option Exercise0.0013,227046,675Aug 02 12:00 AM
Campbell Chad ThomasSVP/GM, Vascular AccessJul 17 '24Option Exercise0.0015,377070,187Aug 02 12:00 AM
Trowbridge Stephen AEVP and CFOJul 17 '24Option Exercise0.0025,9590177,612Aug 02 12:00 AM
Clemmer James CPresident and CEOApr 08 '24Buy6.7010,00067,000539,066Apr 08 12:00 AM
Trowbridge Stephen AEVP and CFOJul 19 '23Option Exercise0.0058,3650133,949Sep 21 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR